Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,342 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07135102RecruitingPhase 1
Radioactive drug for advanced prostate cancer
This study tests an experimental radioactive drug ([225Ac]Ac-PSMA-XT) that targets prostate cancer cells. It is for men whose prostate cancer has spread and stopped responding to standard hormone therapy and chemotherapy.
Jinan, ShandongAges 18 years+ - NCT07130903RecruitingPhase 2
Fruquintinib plus special radio waves for advanced colon cancer
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Bay City, MichiganAges 22 years+ - NCT03401294RecruitingPhase 2
Turn unresectable liver cancer into operable colorectal cancer
This Phase 2 study tests a treatment strategy to shrink or control colorectal cancer that has spread only to the liver, with the goal of making it removable by surgery. If you qualify, it may offer a chance to move from “not operable” to “operable,” but it’s still experimental.
Regina, SaskatchewanAges 18–70 - NCT07124858Recruiting
Fruquintinib for advanced colorectal cancer
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Poitiers, FranceAges 18 years+ - NCT07108114RecruitingPhase 1
SLV-324 for advanced solid tumors that have spread
This phase 1 trial tests a new drug called SLV-324 for people with solid tumors that have spread and are no longer responding to standard treatments. The goal is to see if the drug is safe and works against the cancer.
Newport Beach, CaliforniaAges 18 years+ - NCT07109531RecruitingPhase 3
New drug combo for advanced lung cancer after TKI failure
This trial tests a combination of two experimental drugs (ASKC202 and limertinib) against standard chemotherapy for people with advanced non-small cell lung cancer that has a MET gene change and has stopped responding to earlier targeted therapy (EGFR-TKI). It aims to see if the new combination works better.
ShanghaiAges 18 years+ - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT07086105RecruitingPhase 1
Study of Adze1.C for advanced melanoma
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Southport, QueenslandAges 18 years+ - NCT07093801Recruiting
Study of lutetium-177-PSMA-617 for advanced prostate cancer
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
Alessandria, ALAges 18–99 - NCT07094113RecruitingPhase 1
AMG 410 alone or with other drugs for KRAS-altered advanced cancers
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
Duarte, CaliforniaAges 18 years+ - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07089940RecruitingEarly Phase 1
OMO-103 for advanced pancreatic cancer
This trial tests a new drug called OMO-103 in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It may be an option whether you have had treatment before or not, as long as it's been at least 2 weeks since your last therapy.
Portland, OregonAges 18 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT06972628RecruitingPhase 2
177Lu-PSMA-617 for advanced prostate cancer with bone spread
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Houston, TexasAges 18 years+ - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07076212RecruitingPhase 2
Comparing two chemo combos for advanced pancreatic cancer
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
Charleston, South CarolinaAges 18 years+ - NCT07082439RecruitingPhase 2
Immunotherapy combo for colon cancer spread to the liver
This trial is testing a combination of two drugs (pembrolizumab and odetiglucan) for people with colon or rectal cancer that has spread mainly to the liver. The goal is to see if this combination can shrink tumors and improve outcomes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06980532RecruitingPhase 1/Phase 2
Glumetinib and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
Wuhan, HubeiAges 18 years+ - NCT06912152RecruitingPhase 1
Testing MT027 for advanced belly-lining cancers
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,342 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.